As an Associate Principal with Cello Health BioConsulting, Danielle leads projects focused on market access strategy, opportunity assessments, therapeutic area growth strategy, identification and evaluation of partnering opportunities, and asset valuation. She co-leads the autoimmune and inflammatory disease and metabolics practices at CHBC; however, her experience spans the therapeutic landscape.
Prior to joining Cello Health BioConsulting in 2011, Danielle was a Scientist in the Bioanalytical Development group at an emerging biotech company in New Jersey where she was responsible for the design, development, and validation of a number of immuno- and cell-based assays for use in preclinical and early phase clinical studies for metabolic and autoimmune bone diseases. Danielle was also involved with Business Development efforts to identify potential partners for licensing, as well as competitor mapping in the peptide therapeutic space.
Danielle received a Masters Degree in Cell and Developmental Biology and an MBA with concentrations in Pharmaceutical Management and Marketing from Rutgers University. Her Masters research focused on the NAD-dependent deacetylase, sirtuin-1, and its activity in colon, breast, and pancreatic cancer. She holds a B.S. in Biology from The College of New Jersey.